Result for
Topic: Vaccines and Immunity
April 22, 2021
Immunogenicity of SARS-CoV-2 Vaccine in Dialysis
[Pre-print, not peer-reviewed] 89% of 186 dialysis patients developed anti-SARS-CoV-2 spike antibodies following two doses of mRNA vaccines (Pfizer-BioNTech and Moderna). Among patients without prior SARS-CoV-2 infection (n=148), the seropositivity rate was 86%. A majority (70%) of seropositive patients had maximum titers for anti-spike IgG antibodies at least 14 days after the second dose. No…
Vaccine Breakthrough Infections with SARS-CoV-2 Variants
2 SARS-CoV-2 breakthrough infections (infection >= 14 days after the second vaccine dose) were detected in a cohort of 417 employees at the Rockefeller University in New York City. Clinical symptoms of COVID-19 developed 19 days after Patient 1 (51-year-old woman) received their second dose of the Moderna vaccine, and 36 days after Patient 2…
Effectiveness of the BNT162b2 Vaccine in Preventing COVID-19 in the Working Age Population – First Results from a Cohort Study in Southern Sweden
[Pre-print, not peer-reviewed] The Pfizer-BioNTech vaccine was 86% effective in preventing infection >7 days after the second dose in a cohort study (n=806,000) in Sweden from December 2020 to February 2021. Effectiveness was only 42% >14 days after a single dose. The vaccinated population largely consisted of healthcare workers. SARS-CoV-2 incidence among unvaccinated individuals with…
April 21, 2021
The Risk of Symptomatic Reinfection during the Second COVID-19 Wave in Individuals Previously Exposed to SARS-CoV-2
[Pre-print, not peer-reviewed] In a cohort study in Italy, the adjusted odds ratio for developing symptomatic SARS-CoV-2 infection with SARS-CoV-2 IgG antibodies was 0.05 in the six months following antibody measurement when compared to individuals who were seronegative. The cumulative incidence of laboratory-confirmed, symptomatic infections among IgG-negative and IgG positive cohorts was 2.7% in seronegative…
Postvaccination SARS-CoV-2 Infections Among Skilled Nursing Facility Residents and Staff Members — Chicago, Illinois, December 2020–March 2021
Twenty-two possible breakthrough SARS-CoV-2 infections (infection ≥14 days after the second vaccine dose) were identified among skilled nursing facility staff (n = 10) and residents (n = 12) across 15 facilities in the Chicago, IL area. Among these cases, 14 (64%) were asymptomatic, two residents were hospitalized, and one resident died due to multiple concurrent…
COVID-19 Dynamics after a National Immunization Program in Israel
Two months after the initiation of the SARS-CoV-2 vaccination (Pfizer-BioNTech) campaign in Israel, there were declines in the number of cases (by 77%), percentage of positive tests (by 45%), number of hospitalizations (by 68%), and number of severe hospitalizations (by 67%) compared to peak values. The authors suggest that these results are likely driven by…
A Real World Evaluation of the Safety and Immunogenicity of the Covishield Vaccine ChAdOx1 NCoV- 19 Corona Virus Vaccine (Recombinant) in Health Care Workers (HCW) in National Capital Region (NCR) of India A Preliminary Report
[Pre-print, not peer-reviewed] A real-world study of the safety and immunogenicity of one dose of the Covishield (Oxford-AstraZeneca) vaccine among healthcare workers in India (n = 1,638) found that 79.0% were seropositive 2 weeks after the 1st dose, an increase from the 48.2% who were seropositive at baseline. Among those with prior infection, 98.2% were…
Asymptomatic or Mild Symptomatic SARS-CoV-2 Infection Elicits Durable Neutralizing Antibody Responses in Children and Adolescents
[Pre-print, not peer-reviewed] Children and adolescents with mild or asymptomatic SARS-CoV-2 infection (n = 69) had robust IgM, IgA, and IgG antibody responses to a range of antigens at the time of infection, and at 2- and 4- month follow-up. Neutralizing activity was still detectable 4 months after infection in 94% of participants, and antibody…
April 20, 2021
Serological Investigation of Asymptomatic Cases of SARS-CoV-2 Infection Reveals Weak and Declining Antibody Responses
SARS-CoV-2 anti-nucleocapsid IgM antibodies were detected in a small proportion (6%) of asymptomatic food workers (n=508) in Wuhan in April 2020. In a follow-up survey among 21 of seropositive participants, IgM levels had declined by up to 50% in 90% of individuals. In comparison to a cohort of symptomatic patients 2 months after infection, asymptomatic…
Safety and Immunogenicity of SARS-CoV-2 Recombinant Protein Vaccine Formulations in Healthy Adults: Interim Results of a Randomised, Placebo-Controlled, Phase 1–2, Dose-Ranging Study
The SARS-CoV-2 recombinant protein vaccine candidate CoV2 preS dTM (Sanofi Pasteur) was safe and immunogenic in a randomized Phase I/II trial (n=439) but elicited lower immune responses than anticipated. Both a one and two dose regimen were tested but a single vaccine dose did not generate neutralizing antibody titers above placebo levels in any group….
Previous page Next page